Although asymptomatic grade 3–4 hematologic toxicities, such as neutropenia without fever, can also lead to treatment delays or dose reductions in some situations, these events are generally anticipated consequences of myelosuppressive chemotherapy and are often managed by scheduled monitoring, G-CSF support and short-term adjustments in cycle timing. This evidence concerns the gene CSF3 and Decreased total neutrophil count.